As for future directions, considering that prostate cancer is a frequent location and with long survival, with different treatments depending on the stage of the disease, the genomic profile, the life expectancy, and the patient’s options, including different radiotherapy techniques introduced in the past decade (SBRT), and considering the potential risk of the appearance of the second neoplasm in the irradiated volume, we propose performing molecular biomarker analysis (BRCA 1, BRCA 2, CHEK 2, and CDK12) in metastatic prostate cancer patients and genetic testing in genetic/familial cancers. This evidence concerns the gene CDK12 and hereditary cancer.